Evidence map›Paper›PMID 29755649›Full record

ArticleOncotarget2018

Evaluation of the primitive fraction by functional

María Sol Ruiz, María Belén Sanchez, Leandro Gutiérrez, Daniel Koile, Patricio Yankilevich, Celeste Mosqueira, Santiago Cranco, María Del Rosario Custidiano, Josefina Freitas, Cecilia Foncuberta and 8 more

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 95% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 7 institutions in 1 country.

María Sol RuizCentro de Investigaciones Oncológicas-Fundación Cáncer (CIO-FUCA), Ciudad Autónoma de Buenos Aires, Argentina.
María Belén SanchezCentro de Investigaciones Oncológicas-Fundación Cáncer (CIO-FUCA), Ciudad Autónoma de Buenos Aires, Argentina.
Leandro GutiérrezInstituto de Medicina Experimental, CONICET/Academia Nacional de Medicina, Ciudad Autónoma de Buenos Aires, Argentina.
Daniel KoileInstituto de Investigación en Biomedicina de Buenos Aires (IBioBA), CONICET, Partner Institute of the Max Planck Society, Ciudad Autónoma de Buenos Aires, Argentina.
Patricio YankilevichInstituto de Investigación en Biomedicina de Buenos Aires (IBioBA), CONICET, Partner Institute of the Max Planck Society, Ciudad Autónoma de Buenos Aires, Argentina.
Celeste MosqueiraArgenomics, Ciudad Autónoma de Buenos Aires, Argentina.
Santiago CrancoInstituto Alexander Fleming, Ciudad Autónoma de Buenos Aires, Argentina.
María Del Rosario CustidianoInstituto Alexander Fleming, Ciudad Autónoma de Buenos Aires, Argentina.
Josefina FreitasHospital Nacional Posadas, El Palomar, Buenos Aires, Argentina.
Cecilia FoncubertaInstituto Alexander Fleming, Ciudad Autónoma de Buenos Aires, Argentina.
Beatriz MoiraghiHospital J. M. Ramos Mejía, Ciudad Autónoma de Buenos Aires, Argentina.
Carolina PavlovskyFundaleu, Ciudad Autónoma de Buenos Aires, Argentina.
Mariel Ana PérezHospital Interzonal General de Agudos, Prof. Dr. R. Rossi, La Plata, Buenos Aires, Argentina.
Verónica VentrigliaHospital Nacional Posadas, El Palomar, Buenos Aires, Argentina.
Julio Sanchez ÁvalosInstituto Alexander Fleming, Ciudad Autónoma de Buenos Aires, Argentina.
José MordohCentro de Investigaciones Oncológicas-Fundación Cáncer (CIO-FUCA), Ciudad Autónoma de Buenos Aires, Argentina.
Irene LarripaInstituto de Medicina Experimental, CONICET/Academia Nacional de Medicina, Ciudad Autónoma de Buenos Aires, Argentina.
Michele BianchiniCentro de Investigaciones Oncológicas-Fundación Cáncer (CIO-FUCA), Ciudad Autónoma de Buenos Aires, Argentina.
Fundación para la Investigación, Docencia y Prevención del Cáncer · ARInstituto Alexander Fleming · ARBiomedicine Research Institute of Buenos Aires - CONICET - Partner Institute of the Max Planck Society · ARHospital Posadas · ARAcademia Nacional de Medicina · ARConsejo Nacional de Investigaciones Científicas y Técnicas · ARHospital Ramos Mejía · AR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Quantification of

Indexed as

chronic myeloid leukemialeukemic stem cellspersistencetherapy discontinuationtyrosine-kinase inhibitors

Identifiers

PMID29755649
PMCPMC5945542
OpenAlexW2801249429

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.